A multicenter, prospective, randomized, controlled, open-label clinical study on the efficacy and safety of low-dose apatinib combined with tislelizumab and mXELOX regimen as first-line treatment for elderly patients with advanced gastric/gastroesophageal junction adenocarcinoma

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2025
This article has no abstract
Epistemonikos ID: 82275126a70101e64a50d62c8d2988a65ecb711a
First added on: Apr 24, 2026